GlaxoSmithKline plc is anticipating that demand for its shingles vaccine, depressed over the past year due to COVID-19, will pick up again in the second half of the year and 2022; the company is looking toward that vaccine resilience as well as pipeline development to carry it past its pandemic depression.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?